- Home
- BWAY vs FDMT Comparison
BWAY vs FDMT Comparison
Compare BWAY & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWAY
- FDMT
- Stock Information
- Founded
- BWAY 2003
- FDMT 2013
- Country
- BWAY Israel
- FDMT United States
- Employees
- BWAY N/A
- FDMT N/A
- Industry
- BWAY Medical/Dental Instruments
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- BWAY Health Care
- FDMT Health Care
- Exchange
- BWAY Nasdaq
- FDMT Nasdaq
- Market Cap
- BWAY 201.1M
- FDMT 161.7M
- IPO Year
- BWAY 2019
- FDMT 2020
- Fundamental
- Price
- BWAY $10.22
- FDMT $3.75
- Analyst Decision
- BWAY Strong Buy
- FDMT Buy
- Analyst Count
- BWAY 2
- FDMT 10
- Target Price
- BWAY $14.25
- FDMT $32.33
- AVG Volume (30 Days)
- BWAY 34.0K
- FDMT 448.3K
- Earning Date
- BWAY 05-13-2025
- FDMT 05-08-2025
- Dividend Yield
- BWAY N/A
- FDMT N/A
- EPS Growth
- BWAY N/A
- FDMT N/A
- EPS
- BWAY 0.08
- FDMT N/A
- Revenue
- BWAY $43,457,000.00
- FDMT $23,000.00
- Revenue This Year
- BWAY $351.53
- FDMT $13,097.30
- Revenue Next Year
- BWAY $21.84
- FDMT N/A
- P/E Ratio
- BWAY $51.42
- FDMT N/A
- Revenue Growth
- BWAY 26.86
- FDMT N/A
- 52 Week Low
- BWAY $5.67
- FDMT $2.24
- 52 Week High
- BWAY $11.79
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- BWAY 56.53
- FDMT 57.33
- Support Level
- BWAY $10.15
- FDMT $3.37
- Resistance Level
- BWAY $11.06
- FDMT $3.81
- Average True Range (ATR)
- BWAY 0.51
- FDMT 0.27
- MACD
- BWAY 0.00
- FDMT 0.03
- Stochastic Oscillator
- BWAY 54.72
- FDMT 82.02
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.